1Bergers G, Hanahan D (August 2008). “Modes of resistance
to anti-angiogenic therapy”. Nat. Rev. Cancer. 8
(8): 592–603. doi:10.1038/nrc2442. PMC 2874834.
PMID 18650835.
3Pàez-Ribes, Marta; Allen, Elizabeth; Hudock, James;
Takeda, Takaaki; Okuyama, Hiroaki; Viñals, Francesc;
Inoue, Masahiro; Bergers, Gabriele; Hanahan, Douglas;
Casanovas, Oriol (March 2009). “Antiangiogenic Therapy
Elicits Malignant Progression of Tumors to Increased
Local Invasion and Distant Metastasis”. Cancer Cell. 15
(3): 220–231. doi:10.1016/j.ccr.2009.01.027. PMC
2874829. PMID 19249680. Retrieved 22 October
2012.
2Ebos, John; Christina R. Lee; William Cruz-Munoz;
Georg A. Bjarnason; James G. Christensen; Robert S.
Kerbel (March 2009). “Accelerated Metastasis after
Short-Term Treatment with a Potent Inhibitor of Tumor
Angiogenesis”. Cancer Cell. 15 (3): 232–239.
doi:10.1016/j.ccr.2009.01.021. PMID 19249681. Retrieved
22 October 2012
4Ledermann, Jonathan A; Embleton, Andrew C; Raja,
Fharat; Perren, Timothy J; Jayson, Gordon C; Rustin,
Gordon J S; Kaye, Stan B; Hirte, Hal; Eisenhauer,
Elizabeth; Vaughan, Michelle; Friedlander, Michael;
González-Martín, Antonio; Stark, Daniel; Clark, Elizabeth;
Farrelly, Laura; Swart, Ann Marie; Cook,
Adrian; Kaplan, Richard S; Parmar, Mahesh K B
(2016). “Cediranib in patients with relapsed platinumsensitive
ovarian cancer (ICON6): a randomised,
double-blind, placebo-controlled phase 3 trial”. The
Lancet. 387 (10023): 1066–1074. doi:10.1016/S0140-
6736(15)01167-8. ISSN 0140-6736. PMID 27025186.
